LONDON – The first independent analysis of what the industry is doing to address the threat of antimicrobial resistance (AMR) ranks Glaxosmithkline plc and Johnson & Johnson as first among pharma companies and Astrazeneca plc spinout Entasis Therapeutics Inc. as leader of the biotech pack.